Exclusive: BigHat inks Lilly deal for AI-boosted antibodies, extends Series B

Andrew Dunn

Senior Biopharma Correspondent

BigHat Biosciences has added another pharma partner and more cash to its balance sheet as the antibody specialist prepares to enter the clinic next year …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: BigHat inks Lilly deal for AI-boosted antibodies, extends Series B

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Pharma's wins and losses in Trump's sprawling executive order on drug prices

In a blow to its obesity pipeline, Pfizer drops oral drug after liver injury case

Exclusive: A small biotech will bring Roche's Angelman drug back to life

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

What's Pfizer's next move after shelving its oral obesity drug danuglipron?

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Ex­clu­sive: BigHat inks Lil­ly deal for AI-boost­ed an­ti­bod­ies, ex­tends Se­ries B

Senior Biopharma Correspondent

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Exclusive: BigHat inks Lilly deal for AI-boosted antibodies, extends Series B